Johnson & Johnson reports data from Phase II plaque psoriasis trial

The trial of JNJ-2113 met both its primary and secondary efficacy endpoints.

Vishnu Priyan February 08 2024

Johnson & Johnson has reported results from the Phase II FRONTIER 1 clinical trial of JNJ-2113, an investigational oral peptide inhibitor targeting the IL-23 receptor, for plaque psoriasis (PsO).

The multicentre, double-blind, randomised, placebo-controlled trial is designed to analyse the safety and efficacy of JNJ-2113.

A total of 255 adult patients with moderate-to-severe plaque PsO participated in the study, receiving either three once-a-day or two twice-a-day doses of oral JNJ-2113.

The proportion of subjects attaining a minimum of 75% reduction from baseline in the Psoriasis Area and Severity Index score (PASI 75) at 16 weeks was the primary endpoint.

Secondary endpoints included changes from baseline in PASI score, proportions of subjects attaining PASI 90 and PASI 100 scores, and the number of subjects with an Investigator’s Global Assessment (IGA) score of cleared (0) or minimal (1), among others.

The trial met the primary and all secondary efficacy endpoints.

A substantial dose-response on PASI 75 at week 16 was observed, with 79% of patients in the highest dose group of 100mg twice a day achieving a PASI 75 score.

The highest dose group also saw 40.5% of subjects achieving PASI 100 and 45.2% achieving IGA 0 (clear skin).

Patient-reported outcomes through Week 16 echoed these improvements.

The trial also reported that adverse events (AEs) were generally similar between the JNJ-2113 and placebo groups, with Covid-19 infection, nasopharyngitis and upper respiratory tract infection, among others, being the most frequently seen AEs.

Johnson & Johnson immunodermatology disease area leader and vice-president Lloyd Miller said: “The impacts of living with moderate-to-severe plaque PsO are felt across all aspects of life, and many patients do not seek advanced treatments because they have concerns with injectables and prefer an oral therapeutic option.

“If approved, JNJ-2113 has the potential to improve both clinical and quality of life outcomes.”

Before this, the company announced positive topline results for trials of nipocalimab for generalised myasthenia gravis (gMG) and Sjogren’s disease.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close